aadibio.com (WHWK): Debts to Book Capitalization

Graphic logo of Aadi Bioscience (WHWK)

Biotech development depends on science rather than economics, which is confirmed by the ratio of debt capital to the book capitalization of Aadi Bioscience Inc (WHWK). The value of 0.00 reflects the latest metric value, capturing the level of financial leverage. Fyarro sales growth and M&A potential create a foundation for expansion, while stable demand from oncology centers for targeted therapy for rare sarcomas ensures business resilience.

Aadi Bioscience, Inc. (WHWK) - Debts to Book Value from 03/20/2025 to 10/27/2026
Core merchandise of aadibio.com

Aadi Bioscience Inc (WHWK) faces serious challenges due to the low efficacy of key drugs and spending cuts. This indicator measures the proportion of borrowed funds relative to the total value of equity and debt. Analyzing this structure allows for an assessment of the business's financial autonomy and resilience to crises. It is critical for investors to track the debt-to-equity ratio to understand the risks of underfunding scaling operations. The trend in this debt-to-equity ratio reflects the company's current survival strategy.

Who Aadi Bioscience Inc competes with

ONC - Debt to Book Capitalization Ratio|Debt to Book Value Ratio halozyme.com HALO|RVMD: Debts to Book Capitalization|AAPG - Debt to Book Value|Debts to Book Capitalization CGON|URGN (UroGen Pharma Corp) - Debts to Book Value|BCAX - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio personalis.com (PSNL)|Erasca (ERAS) - Debt to Book Value|Debt to Net Assets Ratio Delcath Systems Inc (DCTH)|YmAbs - Debts to Book Capitalization|AURA - Debt to Book Value|Candel - Debt to Book Value|ARAY: Debts to Book Capitalization|Debt to Book Capitalization Ratio sellaslifesciences.com SLS|Actuate Therapeutics Inc. (ACTU) - Debt to Net Assets Ratio|Debts to Book Capitalization CTOR (Citius Oncology, Inc)|Debts to Book Value TuHURA|Debts to Book Capitalization TARA|Debts to Book Capitalization fatetherapeutics.com (FATE)|Debts to Book Capitalization TCRX (TScan Therapeutics, Inc.)|Debts to Book Capitalization Champions Oncology Inc CSBR|XBiotech USA (XBIT) - Debts to Book Capitalization|CVM - Debt to Book Value Ratio|OS Therapies Incorporated - Debts to Book Capitalization|Debts to Net Assets radiopharmtheranostics.com|ARTV - Debt to Book Value|Debt to Net Assets Ratio Adlai Nortye Limited|Debts to Book Capitalization Veru Pharma (VERU)|Debt to Book Capitalization Ratio Tempest Therapeutics Corp (TPST)|Debts to Book Capitalization XLO|Renovaro Biosciences - Debts to Net Assets|MURA (Mural Bio) - Debt to Book Capitalization Ratio|KAPA: Debts to Book Value|onkuretherapeutics.com - Debt to Book Capitalization Ratio|CytoMed Therapeutics Limited (GDTC) - Debts to Net Assets|Debts to Book Capitalization CRIS|Debt to Book Value Apollomics Corp|THAR (Tharimmune) - Debts to Book Capitalization|Debts to Net Assets advanbiomed.com (ADVB)|GNPX: Debts to Book Capitalization|Calidi Biotherapeutics Inc. - Debts to Book Value|Sunshine Biopharma, Inc. (SBFM) - Debt to Book Capitalization Ratio|XBIO - Debt to Book Value Ratio|SLRX (Salarius Pharmaceuticals, Inc.) - Debts to Book Capitalization|Purple Biotech Ltd (PPBT) - Debt to Book Value|Debts to Book Capitalization AONC (American Oncology Network Inc)|Debts to Book Value BeiGene Ltd (BGNE)|Checkpoint Therapeutics (CKPT) - Debt to Book Value|Debt to Net Assets Ratio elevationoncology.com (ELEV)|Debts to Book Capitalization ICAD|Ikena Oncology Inc. - Debts to Net Assets|Notable Labs Inc. (NTBL) - Debt to Book Capitalization Ratio|VIRX - Debt to Book Value Ratio|MOR (MorphoSys AG) - Debts to Book Capitalization|Debt to Book Value nayabiosciences.com|Debt to Book Value AAPGV